Visual and pharmacotherapy outcomes after transverse sinus stenting for idiopathic intracranial hypertension

Study design, setting and participants

We performed a retrospective chart review of all patients at two neuro-ophthalmology tertiary centres between 2016 and 2022 who underwent TSS for IIH. IIH diagnosis was made by two fellowship-trained neuro-ophthalmologists (EM, JM) according to the modified Dandy criteria.¹ We excluded patients with an identifiable cause for increased ICP, a condition other than IIH that caused vision loss, or less than 1.5 months of follow-up after stenting. Unreliable visual field (VF) tests, defined as false positives >25%, false negatives >30%, or fixation losses >25%, were excluded from data analysis.

Indications for TSS included failure of pharmacotherapy, intolerance of ICP-lowering medications, and fulminant IIH at presentation. Failure of pharmacotherapy was defined as persistence of papilledema and/or continuous visual deterioration despite a maximal daily dose of acetazolamide 3 g or topiramate 200 mg. Fulminant IIH presentation was defined as initial best-corrected visual acuity (VA) worse than 20/40 and/or an initial VF mean deviation (VFMD) worse than -5 dB. This study was approved by the University of Toronto Health Sciences Research Ethics Board and adhered to the tenets of the Declaration of Helsinki.

Study procedure and data collection

All patients underwent comprehensive neuro-ophthalmologic evaluation by a fellowship-trained neuro-ophthalmologist (EM, JM) that included a thorough history, Snellen VA measurement, biomicroscopic examination, VF testing, and peripapillary OCT. Humphrey VF testing (24-2 algorithm) was performed using the Swedish Interactive Thresholding Algorithm (SITA) Fast protocol. A Cirrus spectral-domain OCT unit (Zeiss, Dublin, California, USA) was used to measure the thickness of the peripapillary retinal nerve fibre layer (pRNFL). MRI and magnetic resonance venography (MRV) of the brain were carried out in all patients before TSS. We obtained clinical data from the baseline and most recent follow-up visits as well as interventional data from the stenting report.

Treatment specifications

TSS was performed under general anesthesia in supine position using a biplane neuroangiography system (Philips Allura Xper FD20/20, Eindhoven, The Netherlands). Patients were preloaded with aspirin 81 mg and clopidogrel 75 mg daily for 5 days prior to TSS. First, a cerebral angiography was obtained via 5 French (Fr) radial artery access to visualize the arterial and venous anatomy of the cerebral and cerebellar hemispheres, including a venous 3D rotational angiography of the dural venous sinus. Second, via an 8 Fr common femoral or jugular vein access, pressure measurements were performed with a microcatheter (Excelsior SL-10, Stryker Neurovascular, Hamilton, Ontario, Canada) in the dural venous system proximal and distal to the stenotic segment. Third, after ensuring a trans-stenotic pressure gradient of greater than 5 cm of H₂O, a carotid wall stent measuring 7 × 40 mm (Boston Scientific, Mississauga, Ontario, Canada) was deployed across the stenotic segment, followed by repeat pressure measurements. A 3-month follow-up CTV brain was routinely performed, and double antiplatelet therapy was continued for at least 3 months.

Outcomes

The primary outcome was the proportion of patients for whom ICP-lowering medications were discontinued following TSS. Secondary outcomes included changes in symptomatology, visual function, papilledema severity, and pRNFL thickness between the baseline and most recent follow-up visits. We also examined rates of stenting failure, transverse sinus restenosis, and postoperative complications. Stenting failure was defined as the persistence of papilledema or medication use at the final follow-up. Symptoms considered to indicate raised ICP included headache, pulsatile tinnitus, diplopia secondary to abducens nerve palsy, and transient visual obscurations.

Data analysis

Data were summarized using frequencies and percentages for categorical variables and medians and interquartile ranges (IQR) for continuous variables. The paired Wilcoxon rank sum test with continuity correction was used to compare changes in VA, VFMD, and pRNFL thickness between the baseline visit and most recent visit. The unpaired Wilcoxon rank sum test was used to evaluate whether duration of IIH and duration of symptoms before TSS differed between patients with and without stenting failure. Additionally, the Kendall rank correlation coefficient was used to determine whether IIH and visual symptom duration were associated with visual recovery (i.e. change in VA and change in VFMD). We considered a VA change of ≥0.1 logMAR and a VFMD change of ≥3 dB to be clinically significant. Data analysis was performed using R (version 4.2.1; R Foundation for Statistical Computing, Vienna, Austria). All statistical tests were two-sided and P values <0.05 were considered statistically significant.

Summary of results

In this case series of patients who underwent TSS for IIH, all patients were able to wean off ICP-lowering pharmacotherapy completely (71%) or to a lower dose (29%). Furthermore, all patients demonstrated improvement or resolution of papilledema and ICP-related symptoms after TSS. While most patients demonstrated stable VA post-TSS, VFMD improved in over 85% of patients. Lastly, there were no major TSS-associated complications, and no patient required a subsequent surgical intervention for IIH. One patient experienced postoperative thrombosis at a remote location from stenting.

Comparison to previous literature

Our study adds to the current scarcity of evidence on pharmacotherapeutic outcomes after TSS. Previous studies found that 31%-100% of patients can be weaned off ICP-related pharmacotherapy completely after TSS,^13–20 and that a further 17%-30% can be weaned to lower doses.^13,15,19 Our study showed similar rates of pharmacotherapy discontinuation (71%) and reduction (29%).

Evidence on visual prognosis after TSS is heterogeneous, which is partially attributable to varying inclusion criteria that studies have imposed on baseline visual function and papilledema status. We conducted a literature review of studies that reported post-TSS visual outcomes, applying our study definition of meaningful VA and VFMD change when individual participant data were reported and the original study’s definition if individual participant data were not available. In studies that enrolled patients with both fulminant and non-fulminant IIH, the rate at which visual acuity improves, remains stable, and worsens after TSS ranges from 8%-87%, 14%-92%, and 0%-21%, respectively.^{13,15,18,21–27} For VFMD, these values are 17%-80%, 9%-83%, and 0%-8%, respectively.^{13,15,17,18,21,24,27} Among patients with fulminant IIH, the rate at which visual acuity improves, remains stable, and worsens after TSS ranges from 25-100%, 0-50%, and 25-100%, respectively.^14,21 For VFMD, these values are 75-100%, 0%, and 0-25%, demonstrating less heterogeneity than VA outcomes.^14,16,21 Systematic reviews and meta-analyses have found the rate of VA improvement post-TSS to range from 69% to 78%;^9–11 one meta-analysis combined VA, VFMD, and subjective visual complaints into a composite outcome and found a postoperative improvement rate of 74%.¹² However, none of these systematic reviews provided a quantitative definition of VA change. Our study demonstrated a relatively lower rate of VA improvement but higher rate of VFMD improvement, a pattern that was consistent among the fulminant IIH subgroup. Our literature review similarly demonstrated that VFMD tends to show greater and more consistent improvement after TSS than VA, especially among individuals with fulminant IIH. Thus, we propose that VFMD is a better surrogate for TSS efficacy than VA.

Elder et al. analyzed 4 patients with acute vision loss due to IIH.¹⁴ Inclusion criteria were not clearly described and the patients varied widely with respect to baseline visual function and time to presentation. After TSS, two showed improvement in visual function, one had stable VA but worse VF, and one patient showed deterioration of VA and VF; this patient already had optic atrophy prior to TSS.¹⁴ Notably, all patients were treated with temporary CSF diversion as a bridge to stenting. Our cohort did not receive temporary CSF diversion and had favorable visual outcomes, even in patients with fulminant IIH. Thus, it is unlikely that temporary CSF diversion procedure is necessary in this subgroup of patient and may adversely increase the risk of spinal cord epidural bleeding since patients undergoing TSS require dual platelet anticoagulation.

All patients in our case series experienced improvement or resolution of ICP-related symptoms and papilledema confirmed by peripapillary OCT. This finding is consistent with previous systematic reviews and meta-analyses which demonstrated high rates of papilledema (86%-97%) and symptomatic improvement (overall 87%, headache 78%-83%, tinnitus 85%-95%) after venous sinus stenting.^8–12 None of our patients experienced major complications, developed in-stent thrombosis or restenosis, nor required subsequent surgical intervention for IIH. Meta-analyses of patients undergoing venous sinus stenting for IIH found that major and minor complications occur in less than 3% and 5% of cases, respectively, with a mortality rate of 0%.^8–10,12 Major complications of TSS include intracranial hemorrhage and stroke; minor complications include transient hearing loss, femoral pseudoaneurysm, retroperitoneal hematoma, urinary tract infection, and syncope. The rates of stent survival and stent-adjacent stenosis are estimated to be 84%-100% and 14%, respectively.^9,12 Subsequent surgical treatment for IIH is required in 10%-13% of patients.^8,10–12 Compared to ONSF and CSF diversion procedures, venous sinus stenting leads to similar or better rates of visual recovery, symptomatic improvement, complications, and surgical re-treatment.^10,11 These findings indicate that venous sinus stenting is an efficacious and safe procedure that should be considered in IIH patients who are refractory or intolerant of ICP-lowering pharmacotherapy. Prospective systematic reviews should examine functional, anatomic, and pharmacotherapy outcomes after venous sinus stenting.

Limitations

We acknowledge some important limitations. First, there are inherent biases to the retrospective nature of this study. Second, our study included a small cohort and is likely subject to selection bias favoring inclusion of patients with more severe disease courses, which is an inevitable by-product of strict indications for TSS. Lastly, our patients had a wide range of baseline visual function.

Our study supports TSS as an effective and safe therapeutic modality for patients with medically refractory or fulminant IIH. VF may be a better indicator of treatment success than VA. Prospective, well-powered studies are needed to ascertain the efficacy and safety of TSS. In particular, a multicentre randomized controlled trial should be conducted to compare TSS against CSF diversion procedures, ONSF, and conservative treatment. The effect of time to treatment on VA and VF parameters should be assessed in future research.